7 recruiting, 2 not yet recruiting, 1 active not recruiting, 1 enrolling by invitation. 3 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Head & Neck Squamous Cell Carcinoma: new trials by email Literature Review of Head & Neck Squamous Cell Carcinoma trials Research Report on Head & Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Sutro Biopharma, Inc. | 285 | 2026-10-19 | 2026-10-23 |
| Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI - Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 85 | 2026-08-01 | 2026-08-24 |
| Trilaciclib Combined With Immunochemotherapy for R/M HNSCC Trilaciclib - Head & Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 32 | 2026-06-01 | 2026-07-01 |
| Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy. Head & Neck Squamous Cell Carcinoma | Recruiting | University Hospital, Brest | 180 | 2026-04-13 | 2026-07-13 | |
| Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Bemcentinib, Nimotuzumab, radiotherapy - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 370 | 2026-03-04 | 2026-04-17 |
| Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., placebo capsule, Pembolizumab - Head & Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 45 | 2026-01-27 | 2026-03-20 |
| Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab, intensity-modulated technique（IMRT） - Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 335 | 2026-01-05 | 2026-01-12 |
| A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data Deep Learning, Head & Neck Squamous Cell Carcinoma | Enrolling by invitation | Nanfang Hospital, Southern Medical University | 571 | 2025-08-15 | 2026-07-20 | |
| Longitudinal Oral Health Changes After Head and Neck Radiotherapy Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma | Active not recruiting | Ain Shams University | 100 | 2025-02-01 | 2026-02-06 | |
| Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma | Recruiting | University of Rome Tor Vergata | 25 | 2024-11-20 | 2026-03-04 | |
| A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan. Daily online adaptive radiotherapy - Head & Neck Squamous Cell Carcinoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 40 | 2023-11-21 | 2026-04-02 |
| Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection Tumor Disease Including Colorectal Cancer, Head & Neck Squamous Cell Carcinoma | Unknown | Yonsei University | 400 | 2016-11-04 | 2019-04-02 |
Squamous Cell Carcinoma of Head and Neck (12) · Head and Neck Neoplasms (6) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Dental Caries (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Pathologic Complete Response (1) · Periodontal Diseases (1) · Recurrence (1) · Stomach Neoplasms (1) · Xerostomia (1)
Carcinoma (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Carcinoma, Squamous Cell (11) · Head and Neck Neoplasms (6) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1)
nimotuzumab (2) · Radiotherapy (1) · bemcentinib (1) · pembrolizumab (1) · trilaciclib (1)
Ain Shams University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Fudan University (1) · Gruppo Oncologico del Nord-Ovest (1) · Nanfang Hospital, Southern Medical University (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sutro Biopharma, Inc. (1) · University Hospital, Brest (1) · University of Rome Tor Vergata (1) · Yonsei University (1)
China (4) · Italy (2) · Denmark (1) · Egypt (1) · France (1) · South Korea (1) · United States (1)
Jennifer Oliver (1) · Man Hu (1) · Xiaomin Ou, M.D. (1) · Yu Wang, M.D. (1)